A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

316

Participants

Timeline

Start Date

June 27, 2017

Primary Completion Date

November 27, 2019

Study Completion Date

December 1, 2031

Conditions
Parkinson's Disease
Interventions
DRUG

RO7046015

RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (\>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (\<) 65 kg.

DRUG

RO7046015

RO7046015 will be administered at dose of 1500 mg to all participants in the indicated arm.

DRUG

Placebo

RO7046015 placebo will be administered to all participants in the indicated arm.

Trial Locations (56)

6020

Medizinische Universität Innsbruck, Innsbruck

10032

Columbia University, New York

10117

Klinik fur Neurologie, Berlin

13385

hopital de la Timone, Marseille

14618

University of Rochester Medical Center, Rochester

19107

UNIVERSITY of PENNSYLVANIA, Philadelphia

20014

Policlínica Guipuzcoa, Donostia / San Sebastian

28006

Hospital Universitario de la Princesa, Madrid

28922

Fundacion Hospital de Alcorcon, Alcorcón

31008

Clinica Universidad de Navarra, Pamplona/iruña

31059

CIC - Hôpital Purpan, Toulouse

32806

Compass Research East, LLC, Orlando

33000

Groupe Hospitalier Pellegrin, Bordeaux

33180

Aventura Neurologic Associates, Aventura

33486

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton

33613

USF Parkinsons Disease and Movement Disorders Center, Tampa

34128

Paracelsus Elena Klinik Kassel, Kassel

35043

Philipps Universität Marburg, Marburg

35233

Uab Medicine, Birmingham

37232

Vanderbilt University Medical Center, Nashville

38043

Hôpital Michallon - Centre d'Investigation Clinique, Grenoble

40225

Heinrich-Heine Universitätsklinik Düsseldorf, Düsseldorf

41009

Hospital Universitario Virgen Macarena, Seville

44800

CHU de Nantes - Hopital Laennec, Saint-Herblain

48322

Henry Ford Health System, West Bloomfield

48334

Quest Research Institute, Farmington Hills

49525

Corewell Health Neurology and Epilepsy - Beltline, Grand Rapids

60208

Northwestern University, Evanston

63003

Hopital Gabriel Montpied, Clermont-Ferrand

66160

University of Kansas Medical Center, Kansas City

72076

Universitaettsklinikum Tübingen, Tübingen

74136

The Movement Disorder Clinic of Oklahoma, Tulsa

75013

Hopital Pitie-Salpetriere APHP, Paris

76031

CHU Rouen Charles Nicolle, Rouen

77030

Baylor College, Houston

78681

Central Texas Neurology Consultants, Round Rock

80113

CenExel Rocky Mountain Clinical Research, LLC, Englewood

81377

DZNE Clinical Trial Unit, München

85013

Barrow Neurology Clinics, Phoenix

86021

CHU Poitiers, Poitiers

89081

Universitätsklinikum Ulm, Ulm

90033

USC Keck Medical Center of USC, Los Angeles

92835

Neurology Center of North Orange County, Fullerton

94010

Hopital Henri Mondor, Créteil

94115

University of California at San Francisco, San Francisco

97239

Oregon Health & Science Uni, Portland

06824

Associated Neurologists of Southern CT PC, Fairfield

06510

Molecular Neurolmaging, New Haven

02215

Beth Israel Deaconess Medical Center, Boston

05401

University of Vermont Medical Center, Burlington

06002

CHU de Nice Hopital Pasteur, Nice

04103

Klinik und Poliklinik für Neurologie Universitätsklinikum, Leipzig

08195

Hospital General de Catalunya, Sant Cugat del Vallès

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

08035

Hospital Universitari Vall d'Hebron, Barcelona

08036

Hospital Clinic de Barcelona, Barcelona

All Listed Sponsors
collaborator

Prothena Biosciences Limited

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY